CERT
What one share of Certara holds
Services – Prepackaged Software
We are a global leader in biosimulation science, technology, and consulting services for using Model-Informed Drug Development (“MIDD”) in the global biopharmaceutical and biotech industry. MIDD is an approach that utilizes biological and statistical models derived from preclinical, clinical, and evidence data to inform decision-making in drug research and development, and commercialization.
Certara’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.68 |
|---|---|
| Profit | −$0.43 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | $0.51 |
| Cash and investments | $1.21 |
| Debt | $1.91 |
| Book value | $6.34 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $1.57 | −$0.07 | $0.02 | $0.27 | — | $3.72 |
| 2020 | $1.83 | −$0.37 | $0.01 | $0.33 | — | $5.37 |
| 2021 | $1.91 | −$0.09 | $0.01 | $0.40 | — | $6.53 |
| 2022 | $2.11 | $0.09 | $0.01 | $0.57 | — | $6.77 |
| 2023 | $2.23 | −$0.35 | $0.01 | $0.51 | — | $6.55 |
| 2024 | $2.40 | −$0.08 | $0.01 | $0.49 | — | $6.58 |
| 2025 | $2.61 | −$0.01 | $0.01 | $0.59 | — | $6.68 |